Contents:

FOR EVERY MARKET, SENT QUARTERLY MARKET OUTLOOK Current market size Unique 5-Year market projections to 2012 Market outlook Comment & rating, covering 8 key areas such as use of generic drugs, intellectual property, pricing and the health systems Market structure Statistical data on imports and exports Market developments, covering recent and impending developments with respect to key issues such as regulation, health facilities, funding and government policy Key national data projections FOR EVERY MARKET, SENT ANNUALLY BACKGROUND DATA Population data, including growth trends and age structure Demographic indicators detailing principal causes of death and morbidity HEALTHCARE SYSTEM Organisation & administration Health expenditure - Expenditure by source of funding and type Hospital services - Hospital data such as beds by type, region, specialty, patient admissions and surgical procedures Outpatient care Medical personnel - Data on healthcare professionals covering such areas as doctors by specialty, nursing staff and dentists ACCESSING THE PHARMA MARKET Regulatory environment Distribution guide and trade fair information Domestic production CONTACT DETAILS For healthcare organisations and trade associations

Summary:

7 Key Markets Covered: - Denmark - Estonia - Finland - Latvia - Lithuania - Norway - Sweden Highlights from the region DENMARK Due to the presence of Novo Nordisk, Denmark is a major global supplier of insulin in retail form. This has resulted in a long standing balance of trade surplus. Imports and exports have experienced double-digit growth since 2000. The balance of trade surplus was in excess of US$3.9 billion in 2005. Parallel imported products constitute 12.1% of pharmaceuticals consumed in the primary sector, with a third of respiratory drugs being parallel imported. Although companies are free to set their own prices, products will only be reimbursed at the level of the lowest generic drug in each class unless it can be shown that there is a distinct therapeutic benefit. The government hopes that this will limit the number of ‘me-too’ products that would previously have been reimbursed. SWEDEN The Swedish pharmaceutical market represents approximately 14.1% of total healthcare expenditure and 1.2% of GDP. The market is expected to increase at a rate of 4.6% per year at current dollar prices over the next few years, to be worth in excess of US$5.6 billion by 2012. As is common with other western European countries, Sweden has an advanced healthcare system which is partially privately funded. As a percentage of GDP, health expenditure is above the European average. NORWAY The pharmaceutical market is estimated to be US$2.9 billion in 2007 and is expected to expand by 3.0% per annum over the next five years. Due to limited domestic production much of the market is fed by the import of pharmaceuticals. Although imports increased by 11.8% in 2005, the market for generics, supported by government regulations, accounts for 30.5% in sales or 54.2% by volume. From an international perspective, Norway has a well-developed healthcare system. One of its core values is that everyone should have equal access to good health services funded through public schemes, with an increasing focus on preventative care. LITHUANIA Around 80% of the Lithuanian pharmaceutical market is supplied by imports. In 2005, Germany, Latvia and Belgium were the leading suppliers, accounting for almost 50% of imports. The value of imports has increased every year since 1999. The Lithuanian pharmaceutical industry has failed to attract the interest of foreign manufacturers, unlike other new EU member states, such as Poland or Hungary. A recent legislative change, which makes it difficult for new companies to acquire import licences, may further dissuade pharmaceutical companies from setting up in Lithuania. Sanitas, the largest Lithuanian pharmaceutical company, has more than doubled its sales figures by acquiring two pharmaceutical companies in Central Europe. Sanitas purchased Slovakia’s Hoechst-Biotika in July 2005 and Poland’s Jelfa in April 2006. Sales grew by 174.1% between June 2005 and June 2006 as a result. FINLAND Pharmaceutical expenditure accounts for almost a quarter of total healthcare expenditure, which in turn although increasing year on year, amounts to 7.6% of GDP. In 2007, the Finnish pharmaceutical market was US$3.6 billion, equal to US$694 per capita. There are very few large domestic producers in Finland. The largest, Orion Pharma, claims to hold a market share of approximately 12%. Pfizer Oy and Leiras Oy claim to have market shares of 4.8% and 4.5%, respectively.